REKVINA LABORATORIES LTD.
Latest filings
- MD and Director Amit Shah resigns from Rekvina Labs effective Sept 11, 2026 · Management Changes
- FY26 Annual Report approved, AGM on Sep 29, CS resigns · Management Changes
- 38th AGM on Sep 29 via video conferencing; 2 new independent directors · Board & Shareholder Meetings
- Company Secretary resigns at Rekvina Laboratories · Management Changes
- Promoters raise stake in Rekvina Labs to 60.30% via preferential allotment and open offer · Ownership Changes
- Rekvina Labs: Non-promoter acquirer crosses 10% holding via open offer and preferential allotment · Ownership Changes
- Rekvina Labs Q1 loss widens to Rs 12L; Surbhit Shah named Chairman · Management Changes
- Board Approves Q1 Results, Surbhit Shah Named Chairman · Management Changes
- Allots 50.87 lakh shares on preferential basis for Radiant Parenterals acquisition · Fund Raising
- Board Meeting on 13 Aug 2026 to Approve Q1 FY26 Results · Results
- Open Offer closes: 14.41L shares tendered at Rs 10, acquirers reach 64.3% · Compliance
- Post-offer ad filed for Rekvina open offer: 14.4 lakh shares acquired · Compliance
- Reg 74(5) Compliance Certificate for Quarter Ended June 2026 · Compliance
- Open Offer Update from Rekvina Laboratories · Strategic Transactions
- Pre-Offer Ad filed for Rekvina Labs open offer, tendering from July 1 · Strategic Transactions
- Trading Window Closed Ahead of Q1 FY27 Results · Compliance
- Independent Directors recommend Rekvina open offer as fair · Strategic Transactions
- IDC says open offer at Rs 10 per share is fair and reasonable · Compliance
- Independent Directors say open offer at Rs 10 per share is fair · Strategic Transactions
- Open offer to public shareholders by Vivro Financial Services · Strategic Transactions
- Rekvina Labs Open Offer at Rs 10 per share for 26 percent stake · Strategic Transactions
- Standalone Audited Financial Results for the Quarter ended & Year ended on March 31, 2026 along with statement of Assets & Liabilities, Cash Flow statement & unmodified Audit Report. · Results
- Pursuant to Reg 33 read with Part A of Schedule III of SEBI (LODR) Regulation, 2015, we hereby submitting the following: 1. Standalone Audited Financial Results for the Quarter ended .... · Results
- Rekvina Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve Financial Result for the .... · Results
- Voting Results along with Scrutinizer Report · Board & Shareholder Meetings
- Summary of Proceeding of EGM · Board & Shareholder Meetings
- Non Applicability of Reg- 24(A) - Annual Secretarial Compliance Report · Compliance
- Routine SEBI Reg. 74(5) compliance certificate for Q1 FY26 · Compliance
- Update on Open Offer · Strategic Transactions
- Vivro Financial Services Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Draft Letter of Offer for the attention of the Equity Shareholders of Rekvina Laboratories .... · Strategic Transactions
- Update on Open Offer · Strategic Transactions
- Vivro Financial Services Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Detailed Public Statement for the attention of the Equity Shareholders of Rekvina Laboratories .... · Strategic Transactions
- Trading window will remain closed with effect from, 1st April, 2026 until 48 hours after the declaration of Audited Financial Results by the Company for the Quarter & year ended on March 31, 2026. · Compliance
- Shareholders Meeting - EGM 10.04.2026 · Board & Shareholder Meetings
- Disclosure pursuant to Regulation 30 of SEBI (LODR) Reg 2015 · Strategic Transactions
- Vivro Financial Services Pvt Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Public Announcement for the attention of the Public Shareholders of Rekvina Laboratories Ltd .... · Strategic Transactions
- The Company has approved Preferential Issue of Share through; 1. Swap of Shares 2. Cash Consideration as per attached details. · Fund Raising
- The Board of Directors of the company has approved Increase in Authorized Capital of the company. · Corporate Actions
- Outcome of Board Meeting 16.03.2026 · Board & Shareholder Meetings
- Rekvina Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/03/2026 ,inter alia, to consider and approve the proposal for issuance .... · Fund Raising
- Regulation 33 and Regulation 30 read with Part-A of Schedule III of SEBI (LODR) Regulation, 2015 , we hereby inform you that the Board of Directors of the Company at its meeting held on .... · Results
- Dear Sir/Madam, Pursuant to Regulation 33 and Regulation 30 read with Part-A of Schedule III of SEBI (LODR) Regulations, 2015, we hereby inform you that the Board of Directors of the .... · Results
- Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 , please to informed that Mr. Chetanbhai Patel has tender his resignation from .... · Management Changes
- Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation , 2015, we hereby inform you that the Board of Directors of the Company, at its meeting .... · Management Changes
- Rekvina Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 ,inter alia, to consider and approve Dear Sir/Madam, Pursuant .... · Results
- Pursuant to Regulation 30 of Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that Mr. Dhruvalkumar Jayantilal .... · Management Changes
- In compliance with the Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, please find enclosed herewith copy of certificate received from M/s. Purva Sharegistry .... · Compliance
- Trading window will be closed with effect from, January 01, 2026 until 48 hours after declaration on Un-audited Financial Results · Compliance
- The Paid up capital of the Company is less than Rs. 10/-(Ten) Crores and Net Worth of the Company is less than Rs. 25 /- (Twenty-Five)Crores as on 31.03.2025, so there is non-applicability .... · Compliance
- QTR-2 FINANCIAL RESULT · Results
Snapshot
What the business is, and whether it's a good one at a fair price.
A Pharmaceuticals & Biotechnology company listed on BSE, reporting revenue of ₹2 Cr over the trailing twelve months.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from REKVINA LABORATORIES LTD.'s filed financials and exchange disclosures
What does REKVINA LABORATORIES LTD. do?
REKVINA LABORATORIES LTD. is a Pharmaceuticals & Biotechnology company listed on BSE.
Is REKVINA LABORATORIES LTD. profitable?
No. Over the trailing twelve months REKVINA LABORATORIES LTD. reported a net loss of ₹0 Cr on revenue of ₹2 Cr.
Does REKVINA LABORATORIES LTD. pay a dividend?
Not in the latest reported year — REKVINA LABORATORIES LTD.'s dividend payout for FY26 was nil.
Is REKVINA LABORATORIES LTD. debt-free?
Effectively yes. Debt stands at -1.20× equity.
Is REKVINA LABORATORIES LTD. expensive compared with its peers?
On trailing P/E, REKVINA LABORATORIES LTD. ranks 154 of 170 in Pharmaceuticals — cheaper than 10% of them, against an industry median of 29.6×. This is a position, not a valuation judgement.
How much does the REKVINA LABORATORIES LTD. share price move in a day?
On a typical session REKVINA LABORATORIES LTD. moves 1.99% — that is the median absolute close-to-close move across its last 161 trading days. Announcement days are routinely larger.
Where can I track REKVINA LABORATORIES LTD.'s announcements?
Every NSE and BSE filing by REKVINA LABORATORIES LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.